Communications also continue with the FDA on the
Post# of 72440
Posted On: 11/07/2016 12:49:55 PM
Communications also continue with the FDA on the Company’s Special Protocol Assessment (SPA) request for its planned Phase 3 clinical trial of single-dose Brilacidin in the treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by Gram-positive bacteria.
http://cellceutix.com/cellceutix-novel-anti-i...dications/
Rock and roll baby. People just don't get why this is so friggin important.
http://cellceutix.com/cellceutix-novel-anti-i...dications/
Rock and roll baby. People just don't get why this is so friggin important.
Quote:
FDA approves dangerous new antibiotic on 7-6 vote. Liver toxicity and possibility of permanent harm or death..... but passed because it's the first new antibiotic to treat pneumonia in a long time. (Die now from pneumonia, or later from the antibiotic, some choice.)
http://www.fiercebiotech.com/biotech/fda-pane...0ifQ%3D%3D
So if they approve an antibiotic with these kinds of side effects, does anyone really believe the bashers when they claim that Brilacidin won't be approved because of a possible transient and quickly reversed tingling and possible briefly elevated high blood pressure? Balderdash!
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼